| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun-Ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Kikuchi, Toshiaki Shichijo, Hideaki Tabuse, Shotatsu Koretsune, Hiroshi Terada, Haruko Terada, Toshifumi Kishimoto, Yuichiro Tsutsumi, Kazutaka Oh. Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning. BMC psychiatry. vol 24. issue 1. 2024-09-06. PMID:39237918. |
we report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the japan useful medication program for schizophrenia (jumps), a 104-week naturalistic study. |
2024-09-06 |
2024-09-08 |
Not clear |
| Walaa E Mull. Atypical Antipsychotic-Induced Tardive Dyskinesia in a Middle-Aged Schizophrenic Patient: A Case Report. Cureus. vol 16. issue 7. 2024-09-01. PMID:39205717. |
despite its lower risk profile, aripiprazole can induce td, as illustrated by a 45-year-old woman with schizophrenia who developed severe involuntary movements after five years of stable treatment with this medication. |
2024-09-01 |
2024-09-04 |
Not clear |
| Michael P Caligiuri, Peter J Weiden, Anna Legedza, Sergey Yagoda, Amy Claxto. Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144789. |
adults with acute schizophrenia were assigned to aripiprazole lauroxil or paliperidone palmitate (groups combined for this analysis). |
2024-08-15 |
2024-08-17 |
Not clear |
| Homa Talabaki, Ensiyeh Taghizadeh, Zakaria Zakariae. Extrapyramidal Syndrome due to Aripiprazole Overdose in a Young Woman: An Unusual Case Report. Case reports in medicine. vol 2024. 2024-08-14. PMID:39135879. |
aripiprazole is an atypical antipsychotic medication indicated for the treatment of schizophrenia and bipolar disorders. |
2024-08-14 |
2024-08-16 |
Not clear |
| Jiwan Moon, Hyeryun Yang, Sra Jung, Soo Bong Jung, Jhin-Goo Chang, Won-Hyoung Kim, Sang Min Lee, Jangrae Kim, Minji Bang, Min-Kyoung Kim, Dong-Won Shin, Mi Yeon Lee, Suhyeon Moon, Eun Soo Kim, Sung Joon Ch. Medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy. Progress in neuro-psychopharmacology & biological psychiatry. 2024-08-08. PMID:39116930. |
medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy. |
2024-08-08 |
2024-08-12 |
human |
| Xiaofeng Wang, Mathangi Gopalakrishnan, Benjamin Rich, Jogarao V Gobburu, Frank Larsen, Arash Raoufini. Exposure-Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents. Journal of clinical pharmacology. 2024-07-08. PMID:38973383. |
the aims of this analysis were (1) to quantitatively assess the aripiprazole exposure (average steady-state concentration)-response (positive and negative syndrome scale total score change from baseline) similarity between adults and adolescents with schizophrenia, (2) to extend the aripiprazole exposure-response modeling to brexpiprazole using adult data, and (3) to use the brexpiprazole model to predict schizophrenia symptom response in adolescents. |
2024-07-08 |
2024-07-11 |
Not clear |
| Xiaofeng Wang, Mathangi Gopalakrishnan, Benjamin Rich, Jogarao V Gobburu, Frank Larsen, Arash Raoufini. Exposure-Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents. Journal of clinical pharmacology. 2024-07-08. PMID:38973383. |
disease-drug-dropout models were developed using patient-level data from clinical studies of aripiprazole (1007 adults, 294 adolescents) and brexpiprazole (1235 adults) in schizophrenia. |
2024-07-08 |
2024-07-11 |
Not clear |
| Cun Zhang, Lei Jiang, Ke Hu, Yi-Jia Zhang, Jing Han, Jin Chen, Bulubu, Boling Dong, Hao-Zhe Shi, Su-Mei He, Ting-Ting Yu, Xiao Chen, Dong-Dong Wan. Drug-drug interaction and initial dosage optimization of aripiprazole in patients with schizophrenia based on population pharmacokinetics. Frontiers in psychiatry. vol 15. 2024-07-03. PMID:38957736. |
drug-drug interaction and initial dosage optimization of aripiprazole in patients with schizophrenia based on population pharmacokinetics. |
2024-07-03 |
2024-07-06 |
Not clear |
| Cun Zhang, Lei Jiang, Ke Hu, Yi-Jia Zhang, Jing Han, Jin Chen, Bulubu, Boling Dong, Hao-Zhe Shi, Su-Mei He, Ting-Ting Yu, Xiao Chen, Dong-Dong Wan. Drug-drug interaction and initial dosage optimization of aripiprazole in patients with schizophrenia based on population pharmacokinetics. Frontiers in psychiatry. vol 15. 2024-07-03. PMID:38957736. |
the present study aimed to investigate the drug-drug interaction and initial dosage optimization of aripiprazole in patients with schizophrenia based on population pharmacokinetics. |
2024-07-03 |
2024-07-06 |
Not clear |
| Valerio Ricci, Alessandro Sarni, Giovanni Martinotti, Giuseppe Main. Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review. International clinical psychopharmacology. 2024-06-28. PMID:38941160. |
this narrative review assesses the efficacy, effectiveness, and side effects of third-generation antipsychotics (tgas) like aripiprazole, brexpiprazole, and cariprazine, focusing on their use in first-episode schizophrenia. |
2024-06-28 |
2024-07-01 |
Not clear |
| Aydın Kur. Recurrent Priapism Due to Paliperidone Palmitate Use: A Case Report. Psychiatry and clinical psychopharmacology. vol 32. issue 4. 2024-05-21. PMID:38764879. |
a 51-year-old male who was followed up with a diagnosis of schizophrenia for 30 years and was switched from oral aripiprazole to paliperidone palmitate due to psychotic exacerbation was reported in this study. |
2024-05-21 |
2024-05-27 |
Not clear |
| Xueru Wang, Zijie Li, Shihui Kuai, Xuejiao Wang, Jingyu Chen, Yanping Yang, Ling Qi. Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole. CNS neuroscience & therapeutics. vol 30. issue 5. 2024-05-04. PMID:38702935. |
correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole. |
2024-05-04 |
2024-05-06 |
mouse |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
[atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. |
2024-04-27 |
2024-04-30 |
Not clear |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
the review discusses aspects of the use of atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia using the model of aripiprazole, a partial agonist of dopamine receptors. |
2024-04-27 |
2024-04-30 |
Not clear |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
according to numerous studies, aripiprazole is the drug of choice for augmentative therapy of major depressive disorder, as well as for relieving and long-term maintenance monotherapy and combination therapy of various affective episodes of bipolar affective disorder and depression in schizophrenia. |
2024-04-27 |
2024-04-30 |
Not clear |
| Minji Kang, Seo-Yeong Mun, Wenwen Zhuang, Minju Park, Junsu Jeong, Hongzoo Park, Won-Kyo Jung, Il-Whan Choi, Sunghun Na, Won Sun Par. Inhibition of voltage-gated potassium channel by aripiprazole in rabbit coronary arterial smooth muscle cells. European journal of pharmacology. 2024-04-25. PMID:38663541. |
aripiprazole, a third-generation antipsychotic, has been widely used to treat schizophrenia. |
2024-04-25 |
2024-04-28 |
rabbit |
| Carolina Pinci, Emanuela Bianciardi, Irene Sferra, Giulia Castellani, Riccardo Santini, Alberto Siracusano, Cinzia Niol. Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. Rivista di psichiatria. vol 59. issue 2. 2024-04-23. PMID:38651776. |
switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. |
2024-04-23 |
2024-04-26 |
Not clear |
| Carolina Pinci, Emanuela Bianciardi, Irene Sferra, Giulia Castellani, Riccardo Santini, Alberto Siracusano, Cinzia Niol. Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. Rivista di psichiatria. vol 59. issue 2. 2024-04-23. PMID:38651776. |
to our knowledge, this is the first case report monitoring an entire pregnancy of a women affected by schizophrenia in treatment with pp3m injection and oral aripiprazole. |
2024-04-23 |
2024-04-26 |
Not clear |
| Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V Gobburu, Arash Raoufini. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical pharmacology in drug development. 2024-04-11. PMID:38602057. |
population pharmacokinetics and dosing simulations for aripiprazole 2-month ready-to-use long-acting injectable in adult patients with schizophrenia or bipolar i disorder. |
2024-04-11 |
2024-04-13 |
Not clear |
| Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V Gobburu, Arash Raoufini. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical pharmacology in drug development. 2024-04-11. PMID:38602057. |
a ready-to-use (rtu) long-acting injectable (lai) formulation of aripiprazole monohydrate for administration once every 2 months, available in 960 mg (ari 2mrtu 960) or 720 mg doses, has been developed for the treatment of schizophrenia or bipolar i disorder. |
2024-04-11 |
2024-04-13 |
Not clear |